Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717449 | 0.88 | KMT2A (0.38) | POLBMAPK10KMT2ATSHRALDH1A1 | |
| SCHEMBL1913170 | 0.83 | MAOB (0.36) | KMT2AALDH1A1RXFP1KDM4EMAOB | |
| SCHEMBL21491461 | 0.82 | MAOB (0.42) | KMT2AALDH1A1NPSR1GAAPOLQ | |
| SCHEMBL2013520 | 0.81 | TRIM33 (0.38) | TSHRALDH1A1POLQTRIM33KDM4E | |
| SCHEMBL24770169 | 0.79 | MAOB (0.42) | ALDH1A1GAAPOLQTRIM33KDM4E | |
| SCHEMBL19950938 | 0.79 | GAA (0.43) | POLBKMT2ATSHRGAAPOLQ | |
| SCHEMBL31211997 | 0.77 | KDM4E (0.36) | POLQTRIM33KDM4E | |
| SCHEMBL24460391 | 0.77 | GABRA1 (0.45) | KMT2AALDH1A1GAATDP1KDM4E | |
| SCHEMBL31600582 | 0.77 | HDAC1 (0.42) | POLBKMT2AALDH1A1TDP1KDM4E | |
| SCHEMBL22842993 | 0.76 | TDP1 (0.45) | POLBKMT2ATSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | IDEAYA BIOSCIENCES, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12509454-B2 | Thiadiazolyl derivatives | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| WO-2024254539-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4464709-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118525025-A | Six-membered cyclothiazole compound and application thereof | 南京再明医药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | POLB 1417/4885MAPK10 2579/4885KMT2A 4257/4885 |
| US-20260049074-A1 | THIADIAZOLYL DERIVATIVES | POLH, POLM, POLD1 | POLB 6/4885MAPK10 4278/4885KMT2A 2910/4885 |
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | POLRMT, POLQ, POLH | POLB 6/4885MAPK10 1957/4885KMT2A 1518/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | POLB 2281/4885MAPK10 3208/4885KMT2A 3967/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | POLB 1417/4885MAPK10 2579/4885KMT2A 4257/4885 |
| US-12509454-B2 | Thiadiazolyl derivatives | POLD1, POLQ, DNA2 | POLB 7/4885MAPK10 3009/4885KMT2A 2518/4885 |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | POLB 4539/4885MAPK10 3257/4885KMT2A 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.